Literature DB >> 34889406

Understanding neutropenia secondary to intrinsic or iatrogenic immune dysregulation.

Kelly Walkovich1, James A Connelly2.   

Abstract

As a key member of the innate and adaptive immune response, neutrophils provide insights into the hematopoietic and inflammatory manifestations of inborn errors of immunity (IEI) and the consequences of immunotherapy. The facile recognition of IEI presenting with neutropenia provides an avenue for hematologists to facilitate early diagnosis and expedite biologically rationale care. Moreover, enhancing the understanding of the molecular mechanisms driving neutropenia in IEI-decreased bone marrow reserves, diminished egress from the bone marrow, and decreased survival-offers an opportunity to further dissect the pathophysiology driving neutropenia secondary to iatrogenic immune dysregulation, eg, immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy.
Copyright © 2021 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34889406      PMCID: PMC8791120          DOI: 10.1182/hematology.2021000285

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  75 in total

1.  Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.

Authors:  Noopur Raje; Jesus Berdeja; Yi Lin; David Siegel; Sundar Jagannath; Deepu Madduri; Michaela Liedtke; Jacalyn Rosenblatt; Marcela V Maus; Ashley Turka; Lyh-Ping Lam; Richard A Morgan; Kevin Friedman; Monica Massaro; Julie Wang; Greg Russotti; Zhihong Yang; Timothy Campbell; Kristen Hege; Fabio Petrocca; M Travis Quigley; Nikhil Munshi; James N Kochenderfer
Journal:  N Engl J Med       Date:  2019-05-02       Impact factor: 91.245

2.  Defective granulocyte regulation in the Chediak-Higashi syndrome.

Authors:  R S Blume; J M Bennett; R A Yankee; S M Wolff
Journal:  N Engl J Med       Date:  1968-11-07       Impact factor: 91.245

3.  CD40-ligand stimulates myelopoiesis by regulating flt3-ligand and thrombopoietin production in bone marrow stromal cells.

Authors:  A Solanilla; J Déchanet; A El Andaloussi; M Dupouy; F Godard; J Chabrol; P Charbord; J Reiffers; A T Nurden; B Weksler; J F Moreau; J Ripoche
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

4.  High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia.

Authors:  Marlène Pasquet; Christine Bellanné-Chantelot; Suzanne Tavitian; Naïs Prade; Blandine Beaupain; Olivier Larochelle; Arnaud Petit; Pierre Rohrlich; Christophe Ferrand; Eric Van Den Neste; Hélène A Poirel; Thierry Lamy; Marie Ouachée-Chardin; Véronique Mansat-De Mas; Jill Corre; Christian Récher; Geneviève Plat; Françoise Bachelerie; Jean Donadieu; Eric Delabesse
Journal:  Blood       Date:  2012-12-06       Impact factor: 22.113

Review 5.  Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment.

Authors:  Markus G Seidel
Journal:  Blood       Date:  2014-08-27       Impact factor: 22.113

6.  Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Authors:  Shannon L Maude; Theodore W Laetsch; Jochen Buechner; Susana Rives; Michael Boyer; Henrique Bittencourt; Peter Bader; Michael R Verneris; Heather E Stefanski; Gary D Myers; Muna Qayed; Barbara De Moerloose; Hidefumi Hiramatsu; Krysta Schlis; Kara L Davis; Paul L Martin; Eneida R Nemecek; Gregory A Yanik; Christina Peters; Andre Baruchel; Nicolas Boissel; Francoise Mechinaud; Adriana Balduzzi; Joerg Krueger; Carl H June; Bruce L Levine; Patricia Wood; Tetiana Taran; Mimi Leung; Karen T Mueller; Yiyun Zhang; Kapildeb Sen; David Lebwohl; Michael A Pulsipher; Stephan A Grupp
Journal:  N Engl J Med       Date:  2018-02-01       Impact factor: 91.245

Review 7.  Late Effects after Chimeric Antigen Receptor T cell Therapy for Lymphoid Malignancies.

Authors:  Rajshekhar Chakraborty; Brian T Hill; Aneela Majeed; Navneet S Majhail
Journal:  Transplant Cell Ther       Date:  2020-12-21

Review 8.  Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment.

Authors:  Isabelle Meyts; Ivona Aksentijevich
Journal:  J Clin Immunol       Date:  2018-06-27       Impact factor: 8.317

9.  Hematologic Complications of Immune Checkpoint Inhibitors.

Authors:  Elizabeth J Davis; Joe-Elie Salem; Arissa Young; Jennifer R Green; P Brent Ferrell; Kristin K Ancell; Benedicte Lebrun-Vignes; Javid J Moslehi; Douglas B Johnson
Journal:  Oncologist       Date:  2019-02-28

10.  Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events.

Authors:  Junling Zhuang; Jianhua Du; Xiaoxiao Guo; Jiaxin Zhou; Lian Duan; Wei Qiu; Xiaoyan Si; Li Zhang; Yue Li; Xiaowei Liu; Hanping Wang; Daobin Zhou; Li Zhang
Journal:  Thorac Cancer       Date:  2020-02-03       Impact factor: 3.500

View more
  1 in total

1.  Peripheral-blood cytopenia, an early indicator of inborn errors of immunity.

Authors:  Helena M Cornelissen; Ernest M Musekwa; Richard H Glashoff; Monika Esser; Moleen Zunza; Deepthi R Abraham; Zivanai C Chapanduka
Journal:  Br J Haematol       Date:  2022-07-06       Impact factor: 8.615

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.